Eli Lilly (LLY)

• Market cap: $674B
• 1 day: -1.43%
• 5 days: -0.14%
• 1 month: 6.94%
• 3 months: -1.41%
• 6 months: -10.16%
• Year to date: -3.35%
• 1 year: -17.82%
• 5 years: 397.41%
• 10 years: 758.53%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Employees: 47,000

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

32% more call options, than puts

Call options by funds: $14.1B | Put options by funds: $10.7B

25% more first-time investments, than exits

New positions opened: 217 | Existing positions closed: 173

21% more repeat investments, than reductions

Existing positions increased: 1,737 | Existing positions reduced: 1,434

1% less funds holding

Funds holding: 3,872 [Q1] → 3,843 (-29) [Q2]

3.22% less ownership

Funds ownership: 86.82% [Q1] → 83.6% (-3.22%) [Q2]

10% less capital invested

Capital invested by funds: $678B [Q1] → $608B (-$70.3B) [Q2]

26% less funds holding in top 10

Funds holding in top 10: 388 [Q1] → 286 (-102) [Q2]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $700
• Avg. target: $901
• High target: $1,135

8 analyst ratings

• positive: 6 75%
• neutral: 2 25%
• negative: 0 0%

Berenberg Kerry Holford	$830	Hold Downgraded	17 Sep 2025
JP Morgan Chris Schott	$1,050	Overweight Maintained	16 Sep 2025
HSBC Rajesh Kumar	$700	Hold Upgraded	27 Aug 2025
Guggenheim Seamus Fernandez	$875	Buy Maintained	13 Aug 2025
Cantor Fitzgerald Carter Gould	$825	Overweight Maintained	13 Aug 2025